Zimmer Biomet (ZBH) Stock Price, News & Analysis

-0.37 (-0.31%)
(As of 09:33 AM ET)
Today's Range
50-Day Range
52-Week Range
8,628 shs
Average Volume
1.44 million shs
Market Capitalization
$24.82 billion
P/E Ratio
Dividend Yield
Price Target

Zimmer Biomet MarketRank™ Stock Analysis

Analyst Rating
2.27 Rating Score
15.4% Upside
$139.39 Price Target
Short Interest
2.31% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
1.36mentions of Zimmer Biomet in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$3.36 M Sold Last Quarter
Proj. Earnings Growth
From $8.07 to $8.71 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.79 out of 5 stars

Medical Sector

41st out of 907 stocks

Surgical Appliances & Supplies Industry

2nd out of 18 stocks

ZBH stock logo

About Zimmer Biomet Stock (NYSE:ZBH)

Zimmer Biomet Holdings Inc is a medical technology company that designs, develops and manufactures a wide range of orthopedic and musculoskeletal products. With headquarters in Warsaw, Indiana, the company was formed in 2015 after the merger of Zimmer Holdings and Biomet Inc, two of the world's leading companies in the orthopedic industry. Zimmer Biomet's mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide.

The company's leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017. Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device companies. Additionally, Zimmer Biomet's executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. 

Over the past few years, Zimmer Biomet has reported steady financial performance. The company has reported increased revenue and profit margin for the past several years while also reporting a debt-to-equity ratio indicating a relatively low debt level. In 2021, the company also announced a share repurchase program of up to $1 billion, demonstrating its commitment to returning value to shareholders.

Zimmer Biomet's stock performance has been mixed over the past few years. In early 2020, the company's stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility. 

The orthopedic industry is highly competitive, with a few major players dominating the market. Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets. The industry is also highly regulated, with various regulatory bodies overseeing the safety and efficacy of medical devices. Zimmer Biomet has a track record of complying with regulatory requirements and maintaining high-quality standards.

Zimmer Biomet is expanding its product portfolio through innovation and acquisitions. The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System. Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets.

One of the most significant risks facing Zimmer Biomet is the potential for regulatory changes that could impact the industry. Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet's ability to innovate and compete. In addition, insurance and hospital reimbursement policy changes could also impact the demand for Zimmer Biomet's products.

Another risk facing Zimmer Biomet is the potential for increased competition. While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants. To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development.

Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet's products. For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products.

ZBH Stock Price History

ZBH Stock News Headlines

Intuitive Surgical Leads the Robotic Surgery Movement (ZBH)
Intuitive Surgical is the pioneer in robotic-assisted surgery, investors hope the fifth generation of its da Vinci system can push ISRG stock higher
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Unveiling 7 Analyst Insights On Zimmer Biomet Holdings
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc.
Zimmer Biomet Receives FDA's 510(k) Clearance For ROSA Shoulder System
Q1 2024 Neuroone Medical Technologies Corp Earnings Call
See More Headlines
Receive ZBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/31 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 4/30 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Surgical appliances & supplies
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$1.02 billion
Pretax Margin


Sales & Book Value

Annual Sales
$7.39 billion
Cash Flow
$12.18 per share
Book Value
$59.76 per share


Free Float
Market Cap
$24.90 billion

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Ivan Tornos (Age 49)
    COO, President, CEO & Director
    Comp: $2.72M
  • Mr. Suketu P. Upadhyay (Age 55)
    CFO and Executive VP of Finance, Operations & Supply Chain
    Comp: $2.01M
  • Mr. Chad F. PhippsMr. Chad F. Phipps (Age 52)
    Senior VP, General Counsel & Secretary
    Comp: $1.32M
  • Mr. Sang YiMr. Sang Yi (Age 62)
    President of Asia Pacific
    Comp: $1.38M
  • Mr. Wilfred van Zuilen (Age 54)
    Group President of Europe, Middle East & Africa
    Comp: $1.47M
  • Mr. Paul A. Stellato (Age 49)
    VP, Controller & Chief Accounting Officer
  • Dr. Nitin Goyal M.D.
    Chief Science, Technology & Innovation Officer
  • Mr. Zeeshan Tariq
    Senior VP & Chief Information Officer
  • Ms. Keri P. Mattox
    SVP and Chief Communications & Administration Officer
  • Mr. Zachary Ross Weiner CPA
    Director of Investor Relations

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained


Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

  • Zimmer Biomet Holdings, Inc. operates as a medical technology company worldwide, offering a diverse range of orthopedic reconstructive products, robotic, surgical, and bone cement products. This diversified product portfolio can provide stability and growth potential for investors.
  • The company serves a wide range of specialists and healthcare professionals, including orthopedic surgeons, neurosurgeons, hospitals, and healthcare dealers. This broad customer base can contribute to consistent demand for Zimmer Biomet's products.
  • Recent institutional investments in Zimmer Biomet Holdings, Inc. indicate confidence in the company's future prospects. For example, American Century Companies Inc. raised its stake in the company by 21.2% during the 3rd quarter, reflecting positive sentiment among institutional investors.
  • Wall Street analysts have provided favorable ratings for Zimmer Biomet, with some analysts giving the stock a "buy" or "market outperform" rating. Positive analyst sentiment can attract more investors and potentially drive the stock price higher.
  • Considering the current stock price and the company's financial performance, Zimmer Biomet Holdings, Inc. may present a value investment opportunity for investors looking for long-term growth in the surgical appliances & supplies industry.


Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

  • Despite positive analyst ratings, some analysts have issued cautious outlooks on Zimmer Biomet, such as reducing price targets. Investors should consider the potential risks associated with these cautious views before making investment decisions.
  • While the company has a diverse product portfolio, competition in the medical technology industry is intense. Zimmer Biomet faces competition from other established players, which could impact its market share and profitability.
  • Market volatility and economic uncertainties can affect the demand for medical equipment and surgical appliances. Investors should be aware of external factors that could influence Zimmer Biomet's financial performance and stock price.
  • Changes in healthcare regulations and policies can have a significant impact on Zimmer Biomet's operations and revenue. Investors should monitor regulatory developments closely to assess the potential risks to the company's business.
  • Investors should consider the overall market conditions and macroeconomic factors before investing in Zimmer Biomet Holdings, Inc. Economic downturns or industry-specific challenges could affect the company's growth prospects and stock performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

ZBH Stock Analysis - Frequently Asked Questions

Should I buy or sell Zimmer Biomet stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
View ZBH analyst ratings
or view top-rated stocks.

What is Zimmer Biomet's stock price target for 2024?

15 Wall Street research analysts have issued 12-month target prices for Zimmer Biomet's stock. Their ZBH share price targets range from $120.00 to $172.00. On average, they expect the company's share price to reach $139.39 in the next year. This suggests a possible upside of 15.4% from the stock's current price.
View analysts price targets for ZBH
or view top-rated stocks among Wall Street analysts.

How have ZBH shares performed in 2024?

Zimmer Biomet's stock was trading at $121.70 at the beginning of the year. Since then, ZBH shares have decreased by 0.7% and is now trading at $120.80.
View the best growth stocks for 2024 here

When is Zimmer Biomet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZBH earnings forecast

How can I listen to Zimmer Biomet's earnings call?

Zimmer Biomet will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) issued its quarterly earnings results on Thursday, February, 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating analysts' consensus estimates of $2.15 by $0.05. The medical equipment provider earned $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a trailing twelve-month return on equity of 12.79%. The firm's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.88 EPS.
Read the conference call transcript

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Wednesday, February 21st. Stockholders of record on Friday, March 29th will be given a dividend of $0.24 per share on Tuesday, April 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Wednesday, March 27th.
Read our dividend analysis for ZBH

Is Zimmer Biomet a good dividend stock?

Zimmer Biomet (NYSE:ZBH) pays an annual dividend of $0.96 per share and currently has a dividend yield of 0.79%. The dividend payout ratio is 19.63%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZBH will have a dividend payout ratio of 11.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZBH.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet updated its FY 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 8.000-8.150 for the period, compared to the consensus earnings per share estimate of 7.940. The company issued revenue guidance of $7.7 billion-$7.8 billion, compared to the consensus revenue estimate of $7.7 billion.

What is Bryan Hanson's approval rating as Zimmer Biomet's CEO?

240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com. Bryan Hanson has an approval rating of 87% among the company's employees. 66.0% of employees surveyed would recommend working at Zimmer Biomet to a friend.

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include AT&T (T), Walt Disney (DIS), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Merck & Co., Inc. (MRK), Intel (INTC), AbbVie (ABBV), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.32%), Douglas Lane & Associates LLC (0.25%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), AMF Tjanstepension AB (0.11%), Speece Thorson Capital Group Inc. (0.08%) and Gradient Investments LLC (0.05%). Insiders that own company stock include Arthur J Higgins, Arthur J Higgins, Betsy J Bernard, Chad F Phipps, Michael W Michelson, Robert Hagemann, Sang Yi, Sreelakshmi Kolli and Zuilen Wilfred Van.
View institutional ownership trends

How do I buy shares of Zimmer Biomet?

Shares of ZBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Zimmer Biomet have any subsidiaries?
The following companies are subsidiares of Zimmer Biomet: Abbott Spine, Beijing Montagne Medical Device Co. Ltd., Beijing Montagne Medical Device Co. Ltd., BioMet, Biomet 3i Australia Pty. Ltd., Biomet 3i Belgium N.V., Biomet 3i Benelux Holdings N.V., Biomet 3i Dental Iberica SL, Biomet 3i LLC, Biomet 3i Mexico S.A. de C.V., Biomet 3i Netherlands B.V., Biomet 3i Nordic AB, Biomet 3i Portugal Lda, Biomet 3i Switzerland GmbH, Biomet 3i Turkey, Biomet 3i UK Ltd., Biomet 3i do Brasil Comercio de Aparelhos Medicos Ltda., Biomet Acquisitions (Unlimited), Biomet Argentina SA, Biomet Australia Pty. Ltd., Biomet Biologics LLC, Biomet Brazil Medical Device Ltda., Biomet C.V., Biomet CV Holdings LLC, Biomet Cementing Technologies AB, Biomet Chile SA, Biomet China Co. Ltd., Biomet Deutschland GmbH, Biomet Deutschland Holding GmbH, Biomet Fair Lawn LLC, Biomet Finance US LLC, Biomet France Sarl, Biomet Global Supply Chain Center B.V., Biomet Healthcare Management GmbH, Biomet Holdings B.V., Biomet Hong Kong CBT Ltd., Biomet Hong Kong Holding Ltd., Biomet Hong Kong No. 1 Ltd., Biomet Inc., Biomet Insurance Ltd., Biomet International Inc., Biomet International Orthopedics LLC, Biomet Leasing Inc., Biomet Manufacturing LLC, Biomet Mexico S.A. de C.V., Biomet Microfixation B.V., Biomet Orthopedics LLC, Biomet Orthopedics Puerto Rico Inc., Biomet Spain Orthopaedics S.L., Biomet Sports Medicine LLC, Biomet Trauma LLC, Biomet U.S. Reconstruction LLC, Biomet UK Healthcare Ltd., Biomet UK Ltd., CD Diagnostics, CD Diagnostics Inc., CD Laboratories Inc., Cayenne Medical, Cayenne Medical Inc., CelgenTek Innovations Corporation, Centerpulse Ltd, Changzhou Biomet Medical Devices Co. Ltd., Citra Labs LLC, Clinical Graphics, Compression Therapy Concepts Inc., Compression Therapy Products, D.S. Comp Ltd., Dornoch Medical Systems, Dornoch Medical Systems Inc., EBI Holdings LLC, EBI LLC, EBI Medical Systems LLC, EBI Patient Care Inc., ETEX Corporation, ETEX Holdings Inc., Electro-Biology LLC, Endius, Espanormed S.L., Etex, ExtraOrtho, Hakuho Company Ltd., IC Guided Surgery SRL, Implant Concierge LLC, Implant Innovations Holdings LLC, Implex, InnoVision Inc., Interpore Cross International LLC, JERDS Luxembourg Holding Sarl, Kirschner Medical Corporation, Knee Creations, LDR Brasil Comercio Importacao e Exportacao Ltda., LDR Holding, LDR Medical Hong Kong (branch), LDR Médical S.A.S., LVB Acquisition Inc., Lanx Puerto Rico LLC , Lanx Srl, Medical Compression Systems Inc., Medtech SA, Medtech SAS, Medtech Surgical GmbH, Medtech Surgical Inc., NORMED Medizin-Technik GmbH, ORTHOsoft ULC, Ortho Transmission, Orthopaedic Advantage LLC, Ospol Participacoes Ltda., Representaciones Zimmer Inc. S. de R.L. de C.V., Respondwell, SM Re Ltd., Scandimed Holding AB, Shanghai Biomet Business Consulting Co. Ltd., Synvasive Technology, Synvasive Technology Inc., ZB COOP C.V., ZB COOP LLC, ZB Cayman (Asia) Holding Ltd., ZB Cayman Island CBT 2 Ltd., ZB Dental India Private Limited, ZB EMEA 1 LP, ZB EMEA Finance UK 1 Ltd., ZB EMEA Finance UK 2 Ltd., ZB EMEA Finance UK 3 Ltd., ZB EMEA US UK LLC, ZB Hong Kong CBT 2 Ltd., ZB Hong Kong Holding Ltd., ZB Hong Kong Ltd., ZB Manufacturing LLC, ZB UK Group Holdings Limited, ZH2LX Barbados Branch (branch), Zfx, Zfx GmbH, Zfx Innovation GmbH, Zhejiang Biomet Medical Products Co. Ltd., Zimmer (Shanghai) Medical International Trading Co. Ltd., Zimmer Asia (HK) Ltd., Zimmer Australia Holding Pty. Ltd., Zimmer Biomet (Thailand) Co. Ltd., Zimmer Biomet Asel Alarabiya Limited Company, Zimmer Biomet Asia Holding B.V., Zimmer Biomet Asia Holdings Pte. Ltd., Zimmer Biomet Austria GmbH, Zimmer Biomet BVBA, Zimmer Biomet CBT, Zimmer Biomet CBT 2, Zimmer Biomet CMF and Thoracic LLC, Zimmer Biomet Canada Inc., Zimmer Biomet Centroamerica SA, Zimmer Biomet Comp Ltd., Zimmer Biomet Denmark ApS, Zimmer Biomet Dental Canada Inc., Zimmer Biomet Dental K.K., Zimmer Biomet Deutschland GmbH, Zimmer Biomet Distribution LLC, Zimmer Biomet Finance Srl, Zimmer Biomet Finance US Holding Inc., Zimmer Biomet Finland Oy, Zimmer Biomet France Holdings SAS, Zimmer Biomet France SAS, Zimmer Biomet GK, Zimmer Biomet Global Holdings Switzerland GmbH, Zimmer Biomet Hellas SA, Zimmer Biomet Ireland Limited, Zimmer Biomet Italia Srl, Zimmer Biomet Korea Ltd., Zimmer Biomet Nederland B.V., Zimmer Biomet New Zealand Company, Zimmer Biomet Norway AS, Zimmer Biomet OUS Holdings AG, Zimmer Biomet Polska Sp. z.o.o, Zimmer Biomet Portugal Unipessoal Lda, Zimmer Biomet Pty. Ltd., Zimmer Biomet Romania S.R.L., Zimmer Biomet South Africa (Pty) Ltd., Zimmer Biomet Spain S.L., Zimmer Biomet Spine Inc., Zimmer Biomet Sweden AB, Zimmer Biomet Taiwan Co. Ltd., Zimmer Biomet UK Ltd., Zimmer Biomet US 2 Holding Inc., Zimmer CBT I Holding Inc., Zimmer CBT II Holding Inc., Zimmer CEP USA Holding Co., Zimmer CEP USA Inc., Zimmer CIS Ltd., Zimmer CV Inc., Zimmer Caribe LLC, Zimmer Cayman Islands Holding Co. Ltd., Zimmer Co-op Holdings LLC, Zimmer Colombia SAS, Zimmer Czech sro, Zimmer Dental (Shanghai) Medical Device Co. Ltd., Zimmer Dental Chile Spa, Zimmer Dental GmbH, Zimmer Dental Inc., Zimmer Dental Italy Srl, Zimmer Dental Ltd., Zimmer Dental SAS, Zimmer Finance Ireland, Zimmer France Manufacturing Sarl, Zimmer Germany Holdings GmbH, Zimmer GmbH, Zimmer GmbH Euro IP Branch (branch), Zimmer GmbH Winterthur Branch (branch), Zimmer Gulf FZ LLC, Zimmer Inc., Zimmer India Private Ltd., Zimmer International Logistics GmbH, Zimmer Investments LLC, Zimmer Knee Creations Inc., Zimmer Luxembourg II Sarl, Zimmer Luxembourg Sarl, Zimmer Manufacturing B.V., Zimmer Manufacturing B.V. (branch), Zimmer Medical Malaysia SDN BHD, Zimmer Netherlands Cooperatief U.A., Zimmer Orthobiologics Inc., Zimmer Orthopedics Manufacturing Limited, Zimmer Production Inc., Zimmer Pte. Ltd., Zimmer Slovakia sro, Zimmer Southeast Florida LLC, Zimmer Spine Next Inc., Zimmer Spine SAS, Zimmer Surgical, Zimmer Surgical Inc., Zimmer Surgical SA, Zimmer Switzerland Holdings LLC, Zimmer Switzerland Manufacturing GmbH, Zimmer Tibbi Cihazlar Sanayi ve Ticaret AS, Zimmer Trabecular Metal Technology Inc., Zimmer Trustee Ltd., Zimmer UK Limited, Zimmer US Inc., and Zimmer do Brasil Comercio Ltda..
Read More
This page (NYSE:ZBH) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners